Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct;12(4):769-77.
doi: 10.1007/s13311-015-0383-5.

Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis

William G Notcutt  1
Affiliations
Review

Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis

William G Notcutt. Neurotherapeutics. 2015 Oct.

Abstract

The endocannabinoid system was discovered in 1988 but has received little attention for its potential therapeutic possibilities. That has started to change, and since 2000, a significant number of clinical trials of cannabinoids, principally for the control of spasticity in multiple sclerosis, have been undertaken. These studies have been difficult because of the nature of the disease and have involved patients for whom other therapies have failed or proved inadequate. This paper outlines the background to the use of cannabinoids available and discusses the principles of practice associated with their safe use. The focus has been on nabiximols, being the most studied and the only cannabinoid that has been both adequately researched for use in multiple sclerosis and granted a license by the regulators. However, what has emerged is that the effect for many patients can be much wider than just control of spasticity. Within and outside of neurology there seems to be an expanding range of possibilities for the therapeutic use of cannabinoids.

Keywords: Cannabinoids; multiple sclerosis; nabiximols; pain.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Report from a patient with multiple sclerosis using Sativex (GW Pharmaceuticals, Cambridge, UK) [5]
See this image and copyright information in PMC

References

    1. Scotter EL, Abood ME, Glass M. The endocannabinoid system as a target for the treatment of neurodegenerative disease. Br J Pharmacol. 2010;160:480–498. doi: 10.1111/j.1476-5381.2010.00735.x. - DOI - PMC - PubMed
    1. National Institute for Health and Care Excellence. Multiple sclerosis. Management of multiple sclerosis in primary and secondary care. NICE clinical guideline 186. Available at: http://guidance.nice.org.uk/cg186. Accessed 17 Aug 2015. - PubMed
    1. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci. 2012;367:3353–3363. doi: 10.1098/rstb.2011.0381. - DOI - PMC - PubMed
    1. Skaper RD, Di Marzo V. Why do cannabinoid receptors have more than one endogenous ligand? Philos Trans R Soc Lond B Biol Sci. 2012;367:3216–3228. doi: 10.1098/rstb.2011.0382. - DOI - PMC - PubMed
    1. Notcutt W, Clarke E. Cannabinoids in clinical practice: A UK perspective. In: Pertwee R (ed.) Handbook of cannabis, Oxford University Press, Oxford, 2014; p. 415-432

MeSH terms